A2780 Cell Line
Invented at NIH
A2780cis Cell Line
Invented at NIH
- Datasheet
- References (8)
- Inventor Info
Info
| Catalogue Number | 152708 |
| Antigen/Gene or Protein Targets | Cisplatin resistance |
| Parental Line | A2780 |
| Host | Human |
| Tissue | Ovary |
| Disease Keywords | Human ovarian carcinoma |
| Model | Tumour line |
| Relevance |
A2780 cell line resistant to cisplatin. Background and Research Application The cisplatin-resistant A2780cis cell line has been developed by chronic exposure of the parent cisplatin-sensitive A2780 cell line (catalogue no. 152706) to increasing concentrations of cisplatin. This cell line was derived from a patient with ovarian endometroid adenocarcinoma. A2780cis is cross-resistant to melphalan, adriamycin and irradiation. An increased ability to repair DNA damage as well as cytogenetic abnormalities has been observed. In order to retain resistance cisplatin has to be added to the media for every passage. In addition to this matched pair of drug-sensitive/resistant cell lines an adriamycin-resistant cell line, A2780adr (catalogue no. 152707), has been isolated from the same parental line. A2780cis has been used in a variety of experiments, including studying the cytotoxic effects of platinum (II) complexes and gold (I)-triphenylphosphine complexes with hypoxanthine-derived ligands. It has also been used to study the effects of cancer-cell specific oligopeptides. |
| Production Details | Split sub-confluent cultures (70-80%) 1:5 to 1:20 i.e. seeding at 1x1,000 to 1x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C. Cells will attach slowly after resuscitation and take up to 7 days to reach confluency. Recommendation: resuscitate cells in media without cisplatin. Add after subculture of attached cells. |
| Conditional | No |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Adherant |
| Recommended Growing Conditions | RPMI 1640 + 2mM Glutamine + 1µM cisplatinum + 10% Foetal Bovine Serum (FBS) . |
| Notes |
Points of Interest This cell line has also been used in toxicity testing and drug resistance studies. Karyotype: Modal no. 46 STR-PCR Data: Amelogenin: X CSF1PO: 10,11 D13S317: 13 D16S539: 11,13 D5S818: 11 D7S820: 10 THO1: 6 TPOX: 8,10 vWA: 15,16 Concentration Vial has between 1-5 million cells as standard, however this may vary. |
| Cellosaurus ID | CVCL_1942 |
A2780ADR Cell Line
Invented at NIH
References: 8 entries
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Europe PMC ID: 25230021
Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
Marcotte et al. 2012. Cancer Discov. 2(2):172-189. PMID: 22585861.
Rothenberg et al. 2010. Cancer Res. 70(6):2158-64. PMID: 20215515.
Masuda et al. 1988. Cancer Res. 48(20):5713-6. PMID: 3139281.
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.
Europe PMC ID: 3139281
Behrens et al. 1987. Cancer Res. 47(2):414-8. PMID: 3539322.
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Europe PMC ID: 3539322
Add a reference
References: 8 entries
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
Beaufort et al. 2014. PLoS One. 9(9):e103988. PMID: 25230021.
Marcotte et al. 2012. Cancer Discov. 2(2):172-189. PMID: 22585861.
Rothenberg et al. 2010. Cancer Res. 70(6):2158-64. PMID: 20215515.
Masuda et al. 1988. Cancer Res. 48(20):5713-6. PMID: 3139281.
Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.
Behrens et al. 1987. Cancer Res. 47(2):414-8. PMID: 3539322.
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
Add a reference
